Myeloid Cells in Patients With Covid-19 Pneumonia (NCT04590261) | Clinical Trial Compass
WithdrawnNot Applicable
Myeloid Cells in Patients With Covid-19 Pneumonia
Stopped: The request for an extension was ultimately denied by the CPP because it was submitted after the deadline (the dates on the portal were incorrects).
0Started 2023-09-28
Plain-language summary
The purpose of this study is to analyze in depth the relationship of myeloid cell subpopulations during infection by Severe acute respiratory syndrome coronavirus 2 (SARS-Cov2), the virus mediating Covid-19. Myeloid cells include neutrophils, monocytes and dendritic cells, each divided into subpopulations with different functions in immune defense and immune pathologies.
The study is based on the following hypotheses:
* Infection and the interferon response to infection may induce hyperactive or immunosuppressive differentiation of myeloid cells, that may be treated by specific inhibitors.
* Some myeloid cell subpopulations currently identified in our laboratories might be markers for Covid-19 prognosis.
* Alternative receptors may be present on myeloid cells, inducing the cytokine storm, a target for therapy.
* The expression of Interferon (IFN) receptor and IFN responding genes on myeloid cells and on respiratory epithelial cells may correlate with prognosis and indicate potential treatment targets.
* Interferon responses are known to be skewed during Covid-19, but some IFN subtype polymorphisms may correlate with prognosis and these subtypes migt be supplemented or inhibited for therapy.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \> 18 years
* Sex : male or female
* French Social Security insurance
* Information and consent dated and signed \*
* Group 1 : inclusion 2 to 12 months after hospitalization for Covid-19 pneumonia with mild severity (oxygen treatment ≤5L/mn);
* Group 2 : 2 to 12 months after hospitalization for Covid-19 pneumonia with high severity (oxygen treatment \>5L/mn);
* Group 3 : external visit at Cochin Hospital, age- and sex -matched with Groups 1, 2, 4.
* Group 4 : inclusion during hospitalization for Covid-19, within the first month of symptoms.
Exclusion Criteria:
* Tuberculosis or other evolutive bacterial infection
* Chronic evolutive viral Infections (Hepatitis B or C, HIV)
* Ongoing chemotherapy or radiotherapy
* Participation in another research protocol with current exclusion period at the time of pre-inclusion (possible inclusion in an observational study
* Vulnerable person (pregnant, parturient woman, breastfeeding woman, person Under tutorship, person under arrest through judiciary or administrative decision )
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.